All articles tagged with #drug repurposing
AI is accelerating medicine by personalizing cancer vaccines, repurposing existing drugs for new uses, and guiding treatment decisions with advanced data analysis—evidenced by a melanoma vaccine trial, Castleman-disease treatment via AI, and UCLA’s AI-driven, customized cancer therapy platform—pointing to a future of precision, life-saving care.
MD Anderson researchers found the cancer-promoting protein BRAF may drive chronic neuropathic pain after nerve injury by increasing spinal NMDA receptor activity. In preclinical models, BRAF pathway inhibitors like vemurafenib and the MEK inhibitor selumetinib reduced pain sensitivity without affecting normal pain responses, supporting the potential to repurpose existing cancer drugs for pain relief. Genetic studies further confirmed BRAF’s role in the development and persistence of neuropathic pain. However, these findings are preclinical and require dose, delivery, and safety evaluation before human trials.
Researchers at Northeastern University screened 6,442 drugs and found that oxymetazoline, the active ingredient in Afrin, could improve intercellular communication, a hallmark of aging, suggesting a potential pathway for anti-aging therapies. Human trials don’t exist yet and scientists caution this is early-stage research, not a cure for aging. The piece also notes the drug’s habit-forming nature and mentions aspirin as another drug touching several aging hallmarks, underscoring that further work in cells, animals, and eventually people is needed.
Researchers from Northeastern University and Harvard Medical School developed a framework that links aging-hallmark genes to the human interactome to spot drugs that could affect multiple aging processes, screening 6,442 meds. They pinpointed oxymetazoline (an OTC nasal spray) as a promising candidate that improves cell-to-cell communication, with aspirin also flagged; the study, published in Nature Aging, offers a roadmap for testing repurposed drugs for longevity but does not claim a life-extension cure.
Researchers from Northeastern University and Harvard Medical School developed a framework that links aging hallmarks to clusters in gene/protein networks to identify existing drugs that might slow aging. By mapping about 1,250 aging-related genes onto the human interactome, they pinpointed drugs—such as oxymetazoline and aspirin—that influence multiple aging pathways. While not a guaranteed cure, this approach provides a roadmap for testing candidates in cells, animals, and eventually humans to pursue healthier, longer lifespans.
Medicines often find new uses after their initial purpose; sildenafil, finasteride, and minoxidil were repurposed from heart, prostate, and blood-pressure indications to treat erectile dysfunction and hair loss, illustrating how serendipity and careful observation drive medical progress and highlighting the benefits and caveats of drug repurposing in men's health.
A decades‑old medication has shown in early studies the ability to reprogram white blood cells and improve blood sugar control in type 1 diabetes, signaling a potential new therapeutic avenue that will require larger clinical trials to confirm efficacy and safety.
US researchers used computational analysis to identify two FDA-approved cancer drugs, letrozole and irinotecan, that counteract Alzheimer’s-related gene-expression changes. In mouse models, when used together they reduced tau protein clumps and improved learning and memory, suggesting potential for repurposing and faster clinical testing, though safety in humans and side effects must be evaluated before any trials for Alzheimer's.
Emerging evidence suggests GLP-1 receptor agonists, drugs commonly used to treat diabetes and obesity, may have beneficial effects across multiple cancer types, indicating potential for drug repurposing; further clinical research is needed to confirm efficacy, optimal dosing, and safety.
A new study suggests GLP-1 receptor agonists, drugs commonly used to treat diabetes and obesity, may reduce the risk of cancer spread in certain cancers, a finding that could point to drug repurposing but requires further research to confirm which cancers might benefit and to establish clinical relevance.
A widely used asthma medication may enhance the effectiveness of cancer immunotherapies, potentially improving patient responses when used in combination, though further clinical validation is needed.
Co-Scientist is a Gemini-based multi-agent AI that autonomously generates and refines novel hypotheses, scales test-time compute, and shows in vitro advances in AML drug repurposing and combination therapies, signaling AI-augmented scientific discovery.
A widely used blood pressure medication, candesartan cilexetil, demonstrated in lab and animal studies the ability to kill MRSA by disrupting its cell membrane; when combined with existing antibiotics it enhances effectiveness, with plans to move toward human trials.
University of Barcelona researchers found that pairing two approved drugs, pemafibrate and telmisartan, reversed liver fat in MASLD animal models and may reduce cardiovascular risk; the duo was effective at half-doses together, suggesting synergy and safer therapy. Telmisartan appears to upregulate PCK1, shifting metabolism away from lipid synthesis. Human trials are still needed.
Yale researchers used larval zebrafish to map how 774 FDA-approved drugs affect behaviors tied to autism-risk genes, building an open database of 520 compounds and identifying levocarnitine as a top rescuer for SCN2A and DYRK1A mutations; they validated the effect in human stem-cell–derived neurons, laying groundwork for precision, gene-targeted drug discovery in autism.